- Home
- TRX vs IGMS Comparison
TRX vs IGMS Comparison
Compare TRX & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRX
- IGMS
- Stock Information
- Founded
- TRX 1990
- IGMS 1993
- Country
- TRX Canada
- IGMS United States
- Employees
- TRX N/A
- IGMS N/A
- Industry
- TRX
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- TRX
- IGMS Health Care
- Exchange
- TRX Nasdaq
- IGMS Nasdaq
- Market Cap
- TRX 92.1M
- IGMS 85.0M
- IPO Year
- TRX N/A
- IGMS 2019
- Fundamental
- Price
- TRX $0.31
- IGMS $1.38
- Analyst Decision
- TRX Strong Buy
- IGMS Hold
- Analyst Count
- TRX 2
- IGMS 8
- Target Price
- TRX $1.63
- IGMS $6.14
- AVG Volume (30 Days)
- TRX 397.1K
- IGMS 364.8K
- Earning Date
- TRX 04-11-2025
- IGMS 03-06-2025
- Dividend Yield
- TRX N/A
- IGMS N/A
- EPS Growth
- TRX N/A
- IGMS N/A
- EPS
- TRX 0.01
- IGMS N/A
- Revenue
- TRX $44,282,000.00
- IGMS $2,918,000.00
- Revenue This Year
- TRX $68.64
- IGMS $26.85
- Revenue Next Year
- TRX $22.37
- IGMS $125.17
- P/E Ratio
- TRX $62.24
- IGMS N/A
- Revenue Growth
- TRX 16.51
- IGMS 57.64
- 52 Week Low
- TRX $0.28
- IGMS $1.26
- 52 Week High
- TRX $0.49
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- TRX 44.41
- IGMS 26.21
- Support Level
- TRX $0.30
- IGMS $1.26
- Resistance Level
- TRX $0.34
- IGMS $1.54
- Average True Range (ATR)
- TRX 0.01
- IGMS 0.13
- MACD
- TRX 0.00
- IGMS 0.22
- Stochastic Oscillator
- TRX 6.67
- IGMS 29.27
About TRX TRX Gold Corporation
TRX Gold Corp is a mineral resource company. It is engaged in the acquisition of interests and the exploration of natural resource properties. Its mineral properties are located in the United Republic of Tanzania. The company's main area of interest has been in the exploration and development of gold properties. Its projects include the Buckreef project, and Itetemia Gold project whereas, its exploration stage project consists of the Lunguya project and the Luhala project.
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.